$DEFI

First US Spot Bitcoin ETF Shuts Down as BlackRock's IBIT Swallows the Market

Hashdex Asset Management said it will close and liquidate its US spot Bitcoin ETF, DEFI (NYSE Arca), with Aug. 17, 2026 as the final trading day. As of July 30, 2026, DEFI held about $14.7M (~225 BTC), down from a May 2025 peak of ~$17.54M. A cash distribution is expected around Aug. 28, 2026, based on NAV minus costs.

Original reporting
Published Aug 10, 2026, 4:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 4:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
First US Spot Bitcoin ETF Shuts Down as BlackRock's IBIT Swallows the Market — source image
Decision brief

The 30-second read

$DEFIBearishMed
01

Why it matters

DEFI’s wind-down is a fund-specific event that can drive forced selling mechanics and delisting risk for remaining holders, while also serving as a signal of structural consolidation in the US spot Bitcoin ETF market.

02

Market read

Traders can use the disclosed liquidation timeline to manage DEFI delisting risk and anticipate potential small spot-BTC execution effects during the wind-down window.

03

What to watch

The article does not quantify how quickly DEFI’s remaining BTC will be sold on the open market, which could matter for short-term spot liquidity and execution costs.

Relevance 7/10Novelty 7/10Timing: final trading day Aug 17, liquidation distribution expected around Aug 28

Background

Hashdex launched DEFI as a Bitcoin futures ETF in 2022, converted to a spot Bitcoin ETF in March 2024, and later faced rising fees and scale disadvantages versus early leaders like IBIT.

Company-level read

Ticker impact

$DEFIBearishHigh confidence
Context

Hashdex announced it will close and liquidate the spot Bitcoin ETF DEFI, with final trading day Aug 17 and cash distribution around Aug 28.

Expected impact

Likely negative for DEFI shares into the final trading day, with liquidation NAV uncertainty for holders who do not exit before Aug 17.

Evidence & confidence

The article provides a specific wind-down schedule (final trading day, stop accepting creations, delisting) and states remaining Bitcoin will be sold and proceeds distributed based on NAV minus costs.

Market effects

Reinforces consolidation in US spot Bitcoin ETFs, with smaller funds facing fee and scale pressure versus dominant liquidity leaders.

US-listed spot Bitcoin ETF complex may see minor redistribution of flows away from DEFI into larger, more liquid products.

Limited direct global impact, but supports the broader global trend of winner-take-most in crypto ETPs.

Counterpoint

DEFI’s closure may have limited impact on overall spot Bitcoin demand because the category’s net inflows remain strong and most assets are concentrated in IBIT.

Key entities

  • Hashdex Asset Management

    Announced the closure and liquidation schedule for the Hashdex Bitcoin ETF (DEFI).

  • DEFI

    Hashdex spot Bitcoin ETF on NYSE Arca that will have its final trading day on Aug 17, then be delisted and liquidated.

  • BlackRock iShares Bitcoin Trust (IBIT)

    Dominant US spot Bitcoin ETF referenced as absorbing the majority of category inflows.

Related articles

$IBITMed

Bitcoin ETFs draw $853.5M in five-day inflow streak

U.S. spot Bitcoin ETFs saw five straight net inflow sessions totaling about $853.5 million from Aug. 3 to Aug. 7, reversing the prior week’s $61.5 million net outflows, according to SoSoValue. BlackRock’s IBIT led with about $693 million. Total spot Bitcoin ETF net assets were $79.50B. U.S. spot Ethereum ETFs added about $244.9M over the same period.

$XFORMedAI 8/10

X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures

X4 Pharmaceuticals (XFOR) secured up to $150M in debt financing from K2 HealthVentures, refinancing existing debt and providing additional capital. The initial $80M tranche was used to repay $75M in outstanding debt. The new agreement offers extended repayment terms and supports clinical development, including the potential commercial launch of mavorixafor for chronic neutropenia.

$AVOMed

Mission Produce unveils five-year targets, $100M buyback, aims to double sales and triple EBITDA by 2035

Mission Produce announced a five-year plan with mid-single-digit organic sales growth, 300bps margin expansion, and 2035 targets to double sales to $4B and triple Adjusted EBITDA to $450M. The company reaffirmed fiscal 2H26 Adjusted EBITDA outlook of $84–88M and Q426 Adjusted EBITDA of $52–55M. It also launched a $100M share repurchase program, with 290,994 shares repurchased at an average price of $12.94.